ArticleCancer immunology, immunotherapy : CII2022
Combination immunotherapy including OncoVEX
Open access · greenAbstract read
In one paragraph
Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Review
- Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.Future oncology (London, England) · 2024Review
- The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies.Frontiers in oncology · 2024Review
- Therapy with oncolytic viruses: progress and challenges.Nature reviews. Clinical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 3 countries.
Robyn D GartrellDepartment of Pediatrics, Columbia University Irving Medical Center, 1130 St. Nicholas Avenue, ICRC 916A, New York, NY, 10032, USA.ORCID http://orcid.org/0000-0003-3287-4223
Zoë Blake *Department of Medicine, Columbia University Irving Medical Center, 630 W 168th Street, PS 9-428, New York, NY, 10032, USA.ORCID http://orcid.org/0000-0002-3924-8690
Emanuelle M RizkDepartment of Medicine, Columbia University Irving Medical Center, 630 W 168th Street, PS 9-428, New York, NY, 10032, USA.ORCID http://orcid.org/0000-0003-2831-5592
Rolando Perez-LorenzoDepartment of Dermatology, Columbia University Irving Medical Center, 1150 St. Nicholas Avenue, Russ Berrie Medical Science Pavillion Room 307, New York, NY, 10032, USA.
Stuart P WeisbergDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, 630 W 168th Street, New York, NY, 10032, USA.
Ines SimoesImmunoreceptors del Sistema Innat I Adaptatiu, Institut d'Investigacions Biomediques August Pi I Sunyer, Barcelona, Catalunya, Spain.ORCID http://orcid.org/0000-0003-1730-7263
Camden EsancyHerbert Irving Comprehensicve Cancer Center, Columbia University Irving Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA.
Yichun FuDepartment of Medicine, Mount Sinai Hospital, 1468 Madison Avenue, New York, NY, 10029, USA.
Danielle R DavariUniversity of North Carolina School of Medicine, 140 W Franklin Street, Unit 506, Chapel Hill, NC, 27516, USA.
Luke BarkerValegos College of Physicians and Surgeons, Columbia University, 630 W 168th Street, New York, NY, 10032, USA.
Grace FinkelValegos College of Physicians and Surgeons, Columbia University, 630 W 168th Street, New York, NY, 10032, USA.ORCID http://orcid.org/0000-0002-6030-6293
Manas MondalDepartment of Medicine, Columbia University Irving Medical Center, 630 W 168th Street, PS 9-428, New York, NY, 10032, USA.
Hanna E MinnsDepartment of Pediatrics, Columbia University Irving Medical Center, 1130 St. Nicholas Avenue, ICRC 916A, New York, NY, 10032, USA.ORCID http://orcid.org/0000-0001-7120-5511
Samuel W WangDepartment of Medicine, Columbia University Irving Medical Center, 630 W 168th Street, PS 9-428, New York, NY, 10032, USA.
Benjamin T FullertonDepartment of Medicine, Columbia University Irving Medical Center, 630 W 168th Street, PS 9-428, New York, NY, 10032, USA.ORCID http://orcid.org/0000-0001-7422-5120
Francisco LozanoImmunoreceptors del Sistema Innat I Adaptatiu, Institut d'Investigacions Biomediques August Pi I Sunyer, Barcelona, Catalunya, Spain.
Codruta ChiuzanDepartment of Biostatistics, Columbia University Irving Medical Center, 722 W 168th Street, Room 646, New York, NY, 10032, USA.ORCID http://orcid.org/0000-0001-8169-5032
Basil HorstDepartment of Pathology, University of British Columbia, Vancouver, BC, Canada.
Yvonne M SaengerDepartment of Medicine, Columbia University Irving Medical Center, 630 W 168th Street, PS 9-428, New York, NY, 10032, USA. yms4@cumc.columbia.edu.ORCID http://orcid.org/0000-0001-7074-2681
Columbia University Irving Medical Center · USColumbia University · USConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Clínic de Barcelona · ESMount Sinai Hospital · USUniversity of British Columbia · CAUniversity of North Carolina at Chapel Hill · US
Funding
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MInstitutional Career Development CoreKL2TR001874 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GENKINGER, JEANINE M., SHIMBO, DAICHI · 2016 to 2025
$13.6MNRSA Training CoreTL1TR001875 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SPANN, MARISA N, TAYLOR, JACQUELYN Y · 2016 to 2025
$8.9MTranslational and Precision Medicine Resources Core (TRAP)P30AR069632 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BICKERS, DAVID RINSEY · 2016 to 2020
$3.9MApplying pathomics to establish a biosignature for aggressive skin melanoma.R01CA260375 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Rui Chang, Yvonne Margaret Saenger · 2021 to 2026
$3.1MA prognostic mRNA immune signature for resected stage II-III melanomaUH3CA218149 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SAENGER, YVONNE MARGARET · 2022 to 2024
$1.1MPh1 Study of T-Vec given endoscopically for advanced pancreatic cancer IN 17248 (11/21/2016)R01FD006108 · FDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SAENGER, YVONNE MARGARET · 2018 to 2020
$750kA prognostic mRNA immune signature for resected stage II-III melanomaUH2CA218149 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KROLEWSKI, JOHN J., SAENGER, YVONNE MARGARET · 2019 to 2020
$365kFDA HHS R01 FD006108NCATS NIH HHS KL2 TR001874NCATS NIH HHS TL1 TR001875NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1TR001873NCI NIH HHS R01 CA260375NCI NIH HHS UH3 CA218149NIAMS NIH HHS P30 AR069632NIH HHS 1TL1TR001875-01NIH HHS KL2TR001874NIH HHS R01FD006108
Abstract
Talimogene Laherparepvec (OncoVEX
Indexed as
Antineoplastic AgentsMelanomaOncolytic VirotherapyOncolytic VirusesAnimalsImmunologic FactorsImmunotherapyMiceProto-Oncogene Proteins B-rafTumor MicroenvironmentAntineoplastic AgentsImmunologic FactorsProto-Oncogene Proteins B-rafImmunotherapyMelanomaMicroenvironmentOncolytic virusTumor-infiltrating lymphocyte
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.